The big Alzheimer’s culprits are Amyloid and Tau. Biogen made Leqembi to treat amyloid. Now, they are betting on BIIB080 to treat tau. Learn how this exciting new treatment just got FDA Fast Track Designation.
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
Why can vision loss come before memory loss in 10% of Alzheimer’s? A new study shows Posterior Cortical Atrophy (PCA), a type of Alzheimer’s, distributes proteins differently.
Participants in a new study had inherited genetic variants that lead to early-onset Alzheimer’s. Among those who received the drug the longest – an average of eight years – the treatment lowered the risk of developing symptoms from essentially 100% to about 50%.
Rosemary & sage extracts inspire a potential anti-inflammatory drug for Alzheimer’s. Scripps Research created a stable form of carnosic acid, improving memory in the lab.
The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.
New research suggests antidepressants accelerate cognitive decline in dementia. Learn which drugs appear to be less harmful than others. Help your doctor make better treatment decisions.
(Video & Article) L.A.T.E. Dementia is frequently misdiagnosed as Alzheimer’s. That’s why, in January 2025, researchers created new guidelines. It affects millions of people, approximately 40% of people over 80. How is it recognized? What makes it different?
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise
Plaques are the best-known Alzheimer’s culprit. Cambridge scientists have figured out the 7 steps to forming these plaques. Find out how targeting the formation of these “oligomers” may hold the key to a cure.
UCLA researchers found active people build 5% more gray matter in their brain. See how this prevents Alzheimer’s.
WellnessCheck is a brief, friendly assessment, designed to help you understand your current cognitive wellness. It takes about 3 minutes and covers memory, mood, and focus.
A research study finds when young healthy men had a full, uninterrupted night of rest, their blood levels showed a reduced level of tau, the biomarker for Alzheimer’s disease. The level was higher when they lost just one night of sleep. Learn more.
Here’s a good activity caregivers can use easily, contributed by one of our readers. It’s a simple game, great in mid-stage Alzheimer’s.
Meet Marley, a THERAPAWS therapy dog, helping the elderly that suffer from dementia. See pet therapy at work.
Alzheimer’s is the most common type of dementia, but it is just one cause. In this short Q & A, watch Stanford Neurologist Dr. Kerchner explain the importance of getting an accurate diagnosis.
No spam, only news and updates.
